AMSA injection Pharmaceutical outsourcing project find (CRO) Contract Research Organization
You can contact this pharmacutical clinical contract research projects author: steven
Pharmaceutical outsourcing project name:: AMSA injection
Drug Category: Antineoplastic / other /
want to find a (CRO) Contract Research Organization Location: any
Drugs (CRO) Contract Research description:
Pharmacokinetics: Oral absorption of poor, usually by intravenous injection. Metabolism in the liver by biliary excretion.
The permeability of the blood brain barrier is poor, cerebrospinal fluid content of blood concentrations of less than 20%.
Indications: For acute leukemia and malignant lymphoma. With anthracycline-resistant patients, and Ara-C had no significant
cross-resistance, some patients still valid.
Usage and dosage: Acute leukemia: According to body surface area once 75mg/m2, day 1, intravenous injection or infusion, for
7 days, maximum tolerated dose of 150mg/m2. Solid tumors: According to body surface area a
Times 75 ~ 120mg/m2, 3 ~ 4 Zhou once.
Properties: This product is orange-red clear liquid.
Pharmacology and toxicology: an acridine with a broad-spectrum anti-tumor activity, mechanism similar to the anthracyclines.
An acridine and DNA binding of adenine, thymine base pairs of matching an impact. Main suppression
System, DNA synthesis, pairs of S and G2 phase cells more pronounced inhibition of RNA synthesis was less affected.
Note: 1, bone marrow suppression and heart, liver, nervous system diseases should be used with caution in patients or
appropriate dose reduction; 2, in order to avoid phlebitis, each dose should be diluted to 150ml solution of the above
, The slow intravenous infusion.
Pregnant and lactating women medication: pregnant and lactating women should be careful the FDA.
Medication for children: children's medication without special requirements. Dosage should be adjusted body surface area.
Drug use in elderly patients: no drug use in elderly patients with special requirements. Dosage should be appropriately
reduced.
Adverse reactions: 1, mainly bone marrow suppression, for the dose-limiting toxicity. When the dose reached 90 ~ 120mg/m2,
there can be reduction of platelets and white blood cells; 2, common gastrointestinal reactions, and agents
Volume related. Often appear with low to moderate nausea and vomiting. When the total dose 750mg/m2 or more, prone to
mucositis; 3, heart, liver, nerve toxicity lighter, individual patients may present ventricular heart
The rate of arrhythmia. Fewer allergic reactions and seizures occur, often accompanied by hair loss.
[...your have to login read full text ] OR Free Create AccountSearch other pharmaceutical contract projects?

Loading...